The economic value of a new insulin preparation, Humalog® Mix 25(TM): Measured by a willingness-to-pay approach

PharmacoEconomics

Volumn 18, Issue 3, 2000, Pages 275-287

  Dranitsaris, G ^a   Longo, C J ^b   Grossman, L D ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN LISPRO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0033851240     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018030-00007     Document Type: Article

References (25)

1. Epidemiology of diabetes in Canada
2. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010
3. The economic impact of diabetes
4. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
5. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: A randomized prospective 6-year study
6. (Lys[B28], Pro[B29])-human insulin: A rapidly absorbed analogue of human insulin
7. Intensive insulin therapy with insulin Humalog in patients with type I diabetes reduces the frequency of hypoglycemic episodes
8. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment
9. Clinical outcomes with insulin Humalog compared with regular insulin: A meta analysis
10. Strategies toward improved control during insulin lispro therapy in IDDM
11. Glycemic control in IDDM is improved by optimized combination of insulin lispro and basal insulin
12. Humalog Mix 25 insulin as premeal therapy in type II diabetic patients
13. Improved postprandial glycemic control with Humalog Mix 75/25 after a standard test meal in patients with type 2 diabetes
14. Long term intensive treatment of type I diabetics with the short acting insulin analog Humalog in variable combination with NPH insulin at mealtime
15. When do the 'dollars' make sense? Toward a conceptual framework for contingent valuation studies in health care
16. Using willingness-to-pay as a measure of benefits: What is the relevant question to ask in the context of public decision making about health care problems?
17. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin Humalog-protamine formulations, Insulin Humalog Mix 25 and Insulin Humalog Mix 50
18. Canadian guidelines for economic evaluation of pharmaceuticals
19. Clinical practice guidelines for the management of diabetes in Canada
20. Economic evaluation of insulin Humalog versus neutral insulin therapy using a willingness to pay approach
21. Identification and assessment of prognostic factors
22. What are cancer patients willing to pay for epoetin alfa: A cost-benefit analysis